Engineered immune cells take on viruses in cancer patients
NCT ID NCT05101213
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This early-stage trial tests whether specially designed immune cells (T-cells) can safely control viral infections like CMV, BK virus, or COVID-19 in cancer patients with weakened immune systems. The cells are modified to resist common anti-rejection drugs and target specific viruses. Up to 30 adults who have had a stem cell transplant or have certain cancers will receive these cells. The goal is to see if this approach is feasible and safe, not to cure the underlying cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.